A circadian clock transcription model for the personalization of cancer chronotherapy

Cancer Research

Volumn 73, Issue 24, 2013, Pages 7176-7188

  Li, Xiao Mei ^a,d   Mohammad Djafari, Ali ^e   Dumitru, Mircea ^e   Dulong, Sandrine ^a,d   Filipski, Elisabeth ^a,d   Siffroi Fernandez, Sandrine ^f   Mteyrek, Ali ^a,d   Scaglione, Francesco ^g   Guettier, Catherine ^b   Delaunay, Franck ^f   Lévi, Francis ^a,c,d  

^a INSERM   (France)

^b Bichat hospital Paris   (United States)

^c HÔPITAL PAUL BROUSSE   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e UNIV PARIS SUD   (France)

^f UNIVERSITÉ CÔTE D'AZUR   (France)

^g UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FIRTECAN; IRINOTECAN; MESSENGER RNA; NUCLEAR RECEPTOR NR1D1; PROTEIN BMAL1;

ACCURACY; ADVERSE OUTCOME; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; BMAL1 GENE; CHRONOTHERAPY; CIRCADIAN RHYTHM; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; GENE EXPRESSION REGULATION; GENETIC DIFFERENCE; MALE; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; MOLECULAR CLOCK; MOLECULAR MODEL; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; REV ERB ALPHA GENE; SEX DIFFERENCE; TRANSCRIPTION REGULATION;

ANIMALS; ARNTL TRANSCRIPTION FACTORS; CAMPTOTHECIN; CHRONOTHERAPY; CIRCADIAN CLOCKS; COLONIC NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; INDIVIDUALIZED MEDICINE; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, INBRED DBA; MODELS, BIOLOGICAL; NUCLEAR RECEPTOR SUBFAMILY 1, GROUP D, MEMBER 1; PERIOD CIRCADIAN PROTEINS; RNA, MESSENGER; TOPOISOMERASE I INHIBITORS;

EID: 84891273703     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1528     Document Type: Article

References (49)

1. L-evi F, Okyar A, Dulong S, Innominato PF, Clairambault J. Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol 2010; 50:377-421.
2. L-evi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet 1997;350:681-6.
3. L-evi F, Focan C, Karabou-e A, de la Valette V, Focan-Henrard D, Baron B, et al. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv Drug Deliv Rev 2007;59:1015-35.
4. Innominato PF, Giacchetti S, Moreau T, Smaaland R, Focan C, Bjarnason GA, et al. Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963). Chronobiol Int 2011;28:586-600.
5. Innominato PF, Giacchetti S, Bjarnason GA, Focan C, Garufi C, Coudert B, et al. Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer. Int J Cancer 2012;131:2684-92.
6. Ortiz-Tudela E, Mteyrek A, Ballesta A, Innominato PF, L-evi F. Cancer chronotherapeutics: Experimental, theoretical, and clinical aspects. Handb Exp Pharmacol 2013;217:261-88.
7. L-evi F, Altinok A, Goldbeter A. Circadian rhythms and cancer chronotherapeutics. In:Marcus F, Cesario A, editors. Cancer systems biology, bioinformatics and medicine: Research and clinical applications. Heidelberg, London, New York: Springer Dordrecht; 2011: P. 381-407.
8. Innominato PF, Giacchetti S, Moreau T, Bjarnason GA, Smaaland R, Focan C, et al. Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer. Cancer 2013;119: 2564-73.
9. Levi F, Schibler U. Circadian rhythms: Mechanisms and therapeutic implications. Annu Rev Pharmacol Toxicol 2007;47:593-628.
10. Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F, Okamura H. Control mechanism of the circadian clock for timing of cell division in vivo. Science 2003;302:255-9.
11. Gorbacheva VY, Kondratov RV, Zhang R, Cherukuri S, Gudkov AV, Takahashi JS, et al. Circadian sensitivity to the chemotherapeutic agent cyclophosphamide depends on the functional status of the CLOCK/BMAL1 transactivation complex. Proc Natl Acad Sci U S A 2005;102:3407-12.
12. Gr-echez-Cassiau A, Rayet B, Guillaumond F, Teboul M, Delaunay F. The circadian clock component BMAL1 is a critical regulator of p21 WAF1/CIP1 expression and hepatocyte proliferation. J Biol Chem 2008;283:4535-42.
13. Oklejewicz M, Destici E, Tamanini F, Hut RA, Janssens R, van der Horst GT. Phase resetting of the mammalian circadian clock by DNA damage. Curr Biol 2008;18:286-91.
14. Lee JH, Sancar A. Regulation of apoptosis by the circadian clock through NF-kappaB signaling. Proc Natl Acad Sci U S A 2011;108: 12036-41.
15. Zmrzljak UP, Rozman D. Circadian regulation of endobiotic and xenobitoic detoxification pathways: The time matters. Chem Res Toxicol 2012;25:811-24.
16. Dallmann R, Viola AU, Tarokh L, Cajochen C, Brown SA. The human circadian metabolome. Proc Natl Acad Sci U S A 2012;109:2625-9.
17. Hastings MH, Reddy AB, Maywood ES. A clockwork web: Circadian timing in brain and periphery, in health and disease. Nat Rev Neurosci 2003;4:649-61.
18. Dibner C, Schibler U, Albrecht U. The mammalian circadian timing system: Organization and coordination of central and peripheral clocks. Annu Rev Physiol 2010;72:517-49.
19. Giacchetti S, Bjarnason G, Garufi C, Genet D, Iacobelli S, Tampellini M, et al. Phase III trial of 4-day chronomodulated versus 2-day conventional delivery of fluorouracil, leucovorin and oxaliplatin as first line chemotherapy of metastatic colorectal cancer: The European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol 2006;24:3562-9.
20. Giacchetti S, Dugu-e PA, Innominato PF, Bjarnason GA, Focan C, Garufi C, et al. Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: A meta-analysis. Ann Oncol 2012;23:3110-6.
21. Pommier Y. Topoisomerase I inhibitors: Camptothecins and beyond. Nat Rev Cancer 2006;6:789-802.
22. Kweekel D, Guchelaar HJ, Gelderblom H. Clinical and pharmacogenetic factors associated with irinotecan toxicity. Cancer Treat Rev 2008;34:656-69.
23. Wallace BD, Wang H, Lane KT, Scott JE, Orans J, Koo JS, et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 2010;330:831-5.
24. Ohdo S, Makinosumi T, Ishizaki T, Yukawa E, Higuchi S, Nakano S, et al. Cell cycle-dependent chronotoxicity of irinotecan hydrochloride in mice. J Pharmacol Exp Ther 1997;283:1383-8.
25. Filipski E, Lemaigre G, Liu XH, M-ery-Mignard D, Mahjoubi M, L-evi F. Circadian rhythm of irinotecan tolerability in mice. Chronobiol Int 2004;21:613-30.
26. Granda TG, D'Attino RM, Filipski E, Vrignaud P, Garufi C, Terzoli E, et al. Circadian optimization of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma. Br J Cancer 2002;86:999-1005.
27. Ahowesso C, Piccolo E, Li XM, Dulong S, Hossard V, La Sorda R, et al. Relations between strain and gender dependencies of irinotecan toxicity and UGT1A1, CES2 and TOP1 expressions in mice. Toxicol Lett 2010;192:395-401.
28. Zheng B, Larkin DW, Albrecht U, Sun ZS, Sage M, Eichele G, et al. The mPer2 gene encodes a functional component of the mammalian circadian clock. Nature 1999;400:169-73.
29. Fu L, Pelicano H, Liu J, Huang P, Lee C. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 2002;111:41-50.
30. Schoemaker NE, Rosing H, Jansen S, Schellens JH, Beijnen JH. Ther Drug Monit. High-performance liquid chromatographic analysis of the anticancer drug irinotecan (CPT-11) and its active metabolite SN-38 in human plasma. Ther Drug Monit 2003;25:120-4.
31. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidiniumthiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
32. Iurisci I, Filipski E, Reinhardt J, Bach S, Gianella-Borradori A, Iacobelli S, et al. Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor. Cancer Res 2006;66: 10720-8.
33. Zou H, Hastie T, Tibshirani R. Sparse principal component analysis. J Comput Graph Stat 2006;15:265-86.
34. Qiao Z, Zhou L, Huang JZ. Sparse linear discriminant analysis with applications to high dimensional low sample size data. Int J Appl Math 2008;39:48-60.
35. Mohammad-Djafari A. Bayesian approach with prior models which enforce sparsity in signal and image processing. J Adv Signal Processing 2012:52.
36. Toffoli G, Cecchin E, Corona G, Russo A, Buonadonna A, D'Andrea M, et al. The role of UGT1A1-28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2006;24:3061-8.
37. Chabot GG, Abigerges D, Catimel G, Culine S, de Forni M, Extra JM, et al. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol 1995;6:141-51.
38. Saif MW, Choma A, Salamone SJ, Chu E. Pharmacokinetically guided dose adjustment of 5-fluorouracil: A rational approach to improving therapeutic outcomes. J Natl Cancer Inst 2009;101: 1543-52.
39. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT- 11). Clin Cancer Res 2001;7:2182-94.
40. Hu ZY, Yu Q, Pei Q, Guo C. Dose-dependent association between UGT1A1-28 genotype and irinotecan-induced neutropenia: Low doses also increase risk. Clin Cancer Res 2010;16:3832-42.
41. Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramírez J, Relling M, et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 2009;27: 2604-14.
42. Storch KF, Lipan O, Leykin I, Viswanathan N, Davis FC,WongWH, et al. Extensive and divergent circadian gene expression in liver and heart. Nature 2002;417:78-83.
43. Polidarov-a L, Sot-ak M, Sl-adek M, Pacha J, Sumov-a A. Temporal gradient in the clock gene and cell-cycle checkpoint kinase Wee1 expression along the gut. Chronobiol Int 2009;26:607-20.
44. Gachon F, Olela FF, Schaad O, Descombes P, Schibler U. The circadian PAR-domain basic leucine zipper transcription factors DBP, TEF, and HLF modulate basal and inducible xenobiotic detoxification. Cell Metab 2006;4:25-36.
45. Ma BB, Hui EP, Mok TS. Population-based differences in treatment outcome following anticancer drug therapies. Lancet Oncol 2010;11: 75-84.
46. Wettergren Y, Carlsson G, Odin E, Gustavsson B. Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy. Cancer 2012;118:2935-43.
47. You JS, Jones PA. Cancer genetics and epigenetics: Two sides of the same coin Cancer Cell 2012;22:9-20.
48. Eng C. Toxic effects and their management: Daily clinical challenges in the treatment of colorectal cancer. Nat Rev Clin Oncol 2009;6:207-18.
49. Cleeland CS, Allen JD, Roberts SA, Brell JM, Giralt SA, Khakoo AY, et al. Reducing the toxicity of cancer therapy: Recognizing needs, taking action. Nat Rev Clin Oncol 2012;9:471-8.